Patient characteristics.

Abbreviations: AML, acute myeloid leukemia; sAML, secondary AML; ALL, acute lymphoblastic leukemia; PMF, primary myelofibrosis; CLL: chronic lymphoblastic leukemia; SAA, severe aplastic anemia; Sib: matched sibling donor; PR: partial remission; CR: complete remission; PD: progressive disease; Dupriez score for the prognosis of PMF [29]; Bu, Busulphan; Cy, Cyclophosphamide; Flu, Fludarabin; TBI, Total Body Irradiation; VP-16, Etoposide; the FLAMSA protocol consisted of Fludarabine, Cytosine-Arabinoside and Amsacrine; D, donor; P, patient; M, male; F, female; MMF, Mycophenolate Mofetil; MTX, Methotrexate; CsA, Cyclosporine A; Pred, prednisolone; ATG, Anti-Thymocyte Globulin; Thy, Thymoglobuline; Cam, Campath; PBSC, peripheral blood stem cells; BM, bone marrow; MOF: multi organ failure; aG: acute GvHD graded according Glucksberg score [30]; cG: chronic GvHD graded according Seattle classification [31]; * lower detection limit of the used HA-1H based chimerism assay: 0.01% Patient characteristics.